# Lilly claims one-third of new GLP-1 pill patients

> Eli Lilly CEO says Foundayo is capturing a third of new oral GLP-1 patients as the company breaks ground on a six point five billion dollar Houston manufacturing facility.
- Title: Lilly claims one-third of new GLP-1 pill patients · CNBC
- Summary: Eli Lilly CEO says Foundayo is capturing a third of new oral GLP-1 patients as the company breaks ground on a six point five billion dollar Houston…
- Keywords: eli lilly, foundayo, glp-1 drugs, obesity treatment, manufacturing expansion, houston texas, novo nordisk, medicare coverage, business, finance, Lilly, claims
- Source: CNBC — https://cnbc.com/2026/09/21/lilly-is-ramping-up-future-manufacturing-for-foundayo-obesity-pill.html
- Author: Annika Kim Constantino
- Published: 2026-09-21T16:53:06+00:00
- Read time: 1 min
- Topics: eli lilly, foundayo, glp-1 drugs, obesity treatment, manufacturing expansion, houston texas, novo nordisk, medicare coverage, business, finance
## Lilly claims pill market share
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking Foundayo, the company's oral obesity drug.

> one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo
## Lilly breaks ground in Houston
Lilly broke ground on a six point five billion dollar manufacturing facility at Generation Park in Houston, Texas, expected to be operational by twenty thirty.
## Plant will make Foundayo and more
The Houston facility will produce Foundayo and active ingredients for Lilly's other small-molecule medicines across cardiometabolic health, oncology, immunology and neuroscience.
## Medicare coverage drives demand
Seven hundred thousand U.S. seniors started on GLP-1s after Medicare coverage began on July first, with seventy percent of those patients on Lilly's drugs.
## Foundayo sales accelerate
Foundayo, which entered the U.S. market in April, booked ninety eight million dollars in sales for the second quarter, its first three-month period on the market.
## Lilly's manufacturing bet
Since twenty twenty, Lilly has committed more than fifty billion dollars to expanding its manufacturing network to meet growing demand for obesity and diabetes treatments.
## Key takeaway

Eli Lilly CEO Dave Ricks said one-third of new GLP-1 pill patients are taking Foundayo as the company breaks ground on a six point five billion dollar manufacturing facility in Houston expected to open by twenty thirty.